Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
31 mars 2023 07h00 HE
|
Disc Medicine Inc
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with approximately $194.6 million in cash and cash equivalentsInitiated two Phase 2 trials, AURORA and...
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
21 mars 2023 07h00 HE
|
Disc Medicine Inc
WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
16 févr. 2023 08h00 HE
|
Disc Medicine Inc
WATERTOWN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for...
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
14 févr. 2023 06h30 HE
|
Disc Medicine Inc
WATERTOWN, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
08 févr. 2023 16h00 HE
|
Disc Medicine Inc
WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
20 janv. 2023 07h00 HE
|
Disc Medicine Inc
Disc will obtain exclusive rights to MWTX-003 and other novel anti-TMPRSS6 antibodies in the United States, Europe and other territories excluding Greater China and certain other territories in...
Disc Medicine Announces Completion of Merger with Gemini Therapeutics
29 déc. 2022 17h15 HE
|
Disc Medicine Inc
The combined company will operate as Disc Medicine and will trade on the Nasdaq Global Market under the ticker symbol “IRON”Approximately $175 million of cash and cash equivalents to provide operating...